GHK-Cu 50mg + KPV 10mg Review

This review covers the combined vial format pairing GHK-Cu (Gly-His-Lys-Cu²⁺, 50 mg) with KPV (Lys-Pro-Val, 10 mg), two structurally distinct but functionally complementary research peptides that have accumulated a meaningful body of peer-reviewed literature over the past four decades. GHK-Cu is one of the most studied copper-binding tripeptides in biomedical research, with documented activity across wound healing, skin remodeling, anti-inflammatory signaling, and antioxidant gene expression. KPV is a C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) with documented anti-inflammatory and gut-protective properties in preclinical models.

The decision to package these two peptides together in a single research vial reflects a growing interest among laboratory investigators in combinatorial peptide protocols. Both compounds target overlapping inflammatory and tissue-repair pathways via non-overlapping molecular mechanisms, which makes them scientifically interesting to study in parallel. This review evaluates the chemistry, mechanisms, published research, purity considerations, and pharmacokinetic profiles of both peptides, and situates the Apollo Peptide Sciences product within the broader catalog of available research-grade sources.

Editor's Verdict

The primary advantage of this particular product format is economy of scale for investigators who are already running both peptides in the same experimental context, such as gut-repair studies where both oxidative stress modulation (GHK-Cu) and direct NF-κB suppression (KPV) are relevant endpoints. At $85.00 for 50 mg GHK-Cu plus 10 mg KPV, the effective per-milligram cost compares favorably to purchasing each peptide separately from most research suppliers.

The main limitation is the fixed ratio. Protocols in the literature rarely use GHK-Cu and KPV at a 5:1 mass ratio by default. Researchers who need precise independent titration of each peptide for dose-response studies will find the combined vial format constraining. For endpoint screening or pilot studies, however, the combined vial reduces procurement overhead significantly.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

GHK-Cu: The Copper Tripeptide

GHK-Cu (glycyl-L-histidyl-L-lysine complexed with cupric ion, Cu²⁺) was first isolated from human plasma albumin in 1973 by Loren Pickart, whose doctoral work at the University of California San Francisco identified a small tripeptide fraction capable of stimulating liver cell DNA synthesis in a dose-dependent manner. ^[1] The native peptide GHK exists in circulation at plasma concentrations estimated between 200 nanomolar (in young adults) and as low as 80 nanomolar in older populations, and it binds Cu²⁺ with high affinity (dissociation constant approximately 10⁻¹⁴ M), forming a stable square-planar chelate through the alpha-amino group of glycine, the imidazole nitrogen of histidine, and the epsilon-amino group of lysine. ^[2]

The tripeptide sequence Gly-His-Lys appears to represent a natural tissue-remodeling signal. Pickart and colleagues proposed that GHK-Cu functions as part of a broader "tissue-damage sensing" system: elevated plasma GHK-Cu following injury or inflammation recruits repair processes including fibroblast migration, collagen synthesis, and angiogenesis. ^[3] Structurally, the copper center is essential for full biological activity. Studies comparing GHK (apo-form) with GHK-Cu (holoenzyme) consistently show that the copper-chelated form is more potent at activating metalloprotease systems and stimulating antioxidant responses, although some receptor-binding effects appear to be partially copper-independent. ^[2]

From a synthetic chemistry standpoint, commercial GHK-Cu is produced by solid-phase peptide synthesis (SPPS) of the Gly-His-Lys tripeptide, followed by post-synthetic copper complexation. High-quality batches yield the characteristic blue-green lyophilized powder that reflects the d-d electronic transitions of the Cu²⁺ center coordinated by the three nitrogen donors. The HPLC trace for a pure GHK-Cu sample should show a single dominant peak with retention time consistent with the copper complex; batches where the copper has dissociated (e.g., due to improper pH during processing) may show a shifted or split peak representing uncomplexed GHK alongside free copper salts.

The molecular weight of GHK-Cu is 340.84 g/mol (for the copper complex). The free base tripeptide GHK has a molecular weight of approximately 340.38 g/mol without the copper, but the biologically active research-grade material is always specified as the Cu²⁺ chelate. Researchers should confirm that product specifications explicitly state the copper complex, not the apo-peptide, when ordering.

KPV: The Alpha-MSH C-Terminal Fragment

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH, sequence: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂). The C-terminal tripeptide was identified in the 1990s as the minimal sequence responsible for a significant portion of alpha-MSH's anti-inflammatory bioactivity. ^[4] Unlike alpha-MSH itself, which activates melanocortin receptors (MC1R through MC5R) with high affinity, KPV retains meaningful anti-inflammatory activity through mechanisms that appear partially independent of classical melanocortin receptor engagement, making it an interesting subject of mechanistic research. ^[5]

KPV has a molecular weight of 301.38 g/mol and appears as a white to off-white lyophilized powder. It is freely soluble in water and phosphate-buffered saline across a broad pH range (approximately 4 to 9), which makes reconstitution straightforward compared to more hydrophobic research peptides. Its structure contains a proline residue in the central position, which confers conformational rigidity and resistance to peptidase cleavage compared to linear Ala-X-Ala motifs. This partial protease resistance is relevant to oral administration studies, where KPV has been shown to survive intestinal transit and access epithelial cells in murine models at detectable concentrations. ^[6]

The 10 mg vial quantity in this product reflects the lower literature-reported research concentrations for KPV relative to GHK-Cu. In rodent colitis models, effective IP doses typically range from 100 micrograms to 300 micrograms per kilogram, meaning a 10 mg research vial contains enough material for substantial in-vivo rodent work. For in-vitro cell culture experiments, nanomolar to low-micromolar concentrations are reported as active, meaning a 10 mg vial represents a very large number of experimental wells.

Mechanism of Action

GHK-Cu: Receptor Binding and Downstream Signaling

GHK-Cu does not act through a single, well-characterized receptor-ligand interaction. Its mechanism is better described as pleiotropic signaling modulation mediated by copper ion trafficking, metalloprotease activation, and direct transcriptional effects. The copper in GHK-Cu can be transferred to copper-dependent enzymes including lysyl oxidase and cytochrome c oxidase, where it stimulates enzymatic activity that is directly linked to collagen crosslinking and mitochondrial function, respectively. ^[2]

At the transcriptional level, Pickart and Margolina's 2018 review synthesized evidence that GHK-Cu upregulates a broad gene network through interactions with the Sp1 transcription factor binding sites in gene promoter regions. ^[3] The affected gene network includes numerous collagen subtypes (COL1A1, COL1A2, COL3A1), elastin, decorin, lumican, and several growth factors including vascular endothelial growth factor (VEGF) and nerve growth factor (NGF). Notably, GHK-Cu also activates the antioxidant response element (ARE) pathway, leading to upregulation of superoxide dismutase, catalase, and glutathione S-transferase, which represents a Nrf2-dependent mechanism. ^[7]

GHK-Cu additionally modulates matrix metalloproteinase (MMP) activity in a context-dependent manner. In fibrotic tissue models, it suppresses excess MMP-1, MMP-2, and MMP-9 activity, reducing pathological collagen degradation. Simultaneously, it appears to normalize collagen deposition in wound models by promoting the transition from type III (scar-associated) to type I (mature dermal) collagen, a remodeling phenomenon that several research groups have linked to the activation of transforming growth factor-beta (TGF-beta) signaling through a copper-mediated mechanism. ^[8]

GHK-Cu: Tissue Distribution

Pharmacological tracking of GHK-Cu in animal models shows distribution consistent with a small, hydrophilic copper complex. Following subcutaneous injection in rodent wound models, the peptide accumulates at the site of injury and in surrounding connective tissue within 15 to 30 minutes, with secondary distribution to liver, kidney, and plasma over one to four hours. ^[2] Topically applied GHK-Cu penetrates the stratum corneum, particularly when formulated in vehicles that disrupt the lipid barrier (e.g., liposomal or polyethylene glycol-based preparations), and has been detected in dermal fibroblasts following topical application in ex-vivo skin models. ^[9]

The hepatic distribution is relevant to the peptide's original discovery context. Pickart's initial work identified GHK as a liver-targeted stimulus, and subsequent rodent studies confirmed that IV-administered GHK-Cu preferentially accumulates in hepatic parenchyma relative to most other tissues, with peak hepatic concentrations at approximately 30 minutes post-injection. This distribution profile underlies research interest in GHK-Cu for liver fibrosis models, though this application remains largely preclinical.

KPV: Melanocortin Receptor Engagement and NF-kB Inhibition

KPV's primary mechanistic interest lies in its capacity to inhibit the nuclear factor-kappa B (NF-kB) signaling pathway, which is a central coordinator of inflammatory cytokine production. In a series of experiments by Catania, Lipton, and colleagues, KPV was shown to suppress lipopolysaccharide (LPS)-induced NF-kB activation in macrophages and monocytes at concentrations in the low-micromolar range. ^[4] The mechanism involves inhibition of IkB kinase (IKK) activity, which prevents phosphorylation and degradation of IkBα, thereby retaining the p65/p50 NF-kB heterodimer in the cytoplasm and blocking transcription of pro-inflammatory target genes including TNF-alpha, IL-1beta, IL-6, and IL-8.

KPV also retains residual activity at melanocortin receptor subtypes MC1R and MC3R, both of which are expressed on immune cells (monocytes, macrophages, dendritic cells, T cells) and mediate anti-inflammatory cAMP-PKA signaling. ^[5] The relative contribution of melanocortin receptor-dependent versus receptor-independent mechanisms to KPV's observed effects is an area of active investigation. Some studies using MC1R-null cell lines still observe KPV-mediated NF-kB suppression, suggesting a meaningful receptor-independent component. Others identify MC3R as the primary mediator in gut epithelial contexts.

KPV: Gut-Barrier and Epithelial Signaling

A particularly active area of KPV research concerns its interaction with gut epithelial biology. The intestinal epithelium expresses PepT1 (SLC15A1), a proton-coupled oligopeptide transporter that actively transports di- and tri-peptides across the brush border. Dalmasso and colleagues demonstrated that KPV is a substrate for PepT1, enabling its uptake into intestinal epithelial cells and subsequent intracellular NF-kB inhibition at concentrations that would be subthreshold for receptor-level melanocortin engagement. ^[6] This transporter-mediated mechanism is significant because it provides a plausible route of action for orally administered KPV without requiring systemic absorption, making it relevant to local gut-inflammatory models.

Within intestinal epithelial cells, KPV also activates PPAR-gamma (peroxisome proliferator-activated receptor gamma), a nuclear receptor with well-established anti-inflammatory and barrier-restorative properties. PPAR-gamma activation in colonocytes promotes expression of tight-junction proteins (occludin, claudin-1, ZO-1) and reduces paracellular permeability, which is a direct structural correlate of barrier integrity. The combination of NF-kB inhibition plus PPAR-gamma activation makes KPV's intracellular profile in gut epithelium distinct from most anti-inflammatory peptides that act exclusively through surface receptor antagonism.

What the Research Says

Study 1: Pickart (1973) - Original Identification of GHK

Pickart's foundational 1973 study, published in the Journal of Theoretical Biology, established the existence of GHK as a growth-modulating tripeptide fragment isolated from human plasma albumin. ^[1] The study used hepatocyte culture assays to demonstrate that the peptide fraction stimulated DNA synthesis in a dose-dependent fashion, with maximal activity at concentrations consistent with physiological plasma levels. While the experimental design used in 1973 would be considered preliminary by contemporary standards (no receptor characterization, no gene expression analysis), the identification of the Gly-His-Lys sequence was accurate and has been repeatedly confirmed by mass spectrometric analysis in subsequent decades.

The study's main contribution was demonstrating that a plasma-derived tripeptide, rather than a larger growth factor protein, could stimulate hepatocyte proliferative signaling. This challenged the prevailing view that growth signals required large polypeptides and opened a research direction that ultimately connected copper metabolism, tripeptide signaling, and tissue repair. The limitation is that Pickart's own group dominated much of the early GHK-Cu literature, creating a concentration of authorship that warrants critical reading of replication studies.

Study 2: Pickart et al. (2012) - GHK-Cu and Wound Healing Gene Expression

In a 2012 paper in the Archives of Dermatological Research, Pickart and collaborators used Affymetrix gene-chip arrays to characterize the transcriptional response of human fibroblasts treated with GHK-Cu at concentrations of 1 nM to 10 uM over 24 and 72 hours. ^[3] The study identified approximately 4,000 genes whose expression changed by at least 1.5-fold in response to GHK-Cu treatment, with the largest clusters enriched in collagen biosynthesis, MMP regulation, antioxidant response, and neurotrophic signaling pathways.

The sample size was limited to a small number of primary fibroblast preparations from human donors, which is a common constraint in cell-culture transcriptomics studies. However, the consistency of pathway enrichment across multiple donors strengthened the biological interpretation. The study identified GHK-Cu as one of the most pleiotropic small-peptide modulators of fibroblast gene expression reported at that time, a claim that has held up in subsequent network biology analyses. The antioxidant gene activation component (SOD, catalase, glutathione peroxidase) was particularly notable because it suggested a Nrf2-mediated mechanism operating in parallel with the growth-factor-like transcriptional effects.

Study 3: Dalmasso et al. (2008) - KPV, PepT1, and Colitis

Dalmasso and colleagues published a study in 2008 in Gastroenterology that is widely considered the pivotal mechanistic paper for KPV's gut-related biology. ^[6] Using DSS-induced colitis in C57BL/6 mice (n = 12-15 per group), the researchers administered KPV at 100 ug/kg IP and also via oral gavage, comparing both routes to vehicle control and to the full alpha-MSH peptide.

Both IP and oral KPV significantly reduced colon length shortening (a morphological endpoint for colitis severity), decreased histological inflammation scores, and reduced colonic mucosal expression of TNF-alpha, IL-1beta, and IL-6 by 40 to 65% compared to vehicle. Oral KPV was slightly less potent than IP KPV, consistent with some peptide degradation in transit, but retained statistically significant anti-inflammatory effects. Crucially, the study demonstrated using radiolabeled KPV that the peptide was actively transported into colonocytes via PepT1, with uptake abolished in PepT1-knockout cells. This confirmed the transporter-mediated mechanism and provided the first evidence that a tripeptide could access intracellular NF-kB machinery via an active transport route rather than endocytosis or diffusion.

The main limitation of this study was the use of a chemical colitis model (DSS), which does not fully recapitulate the immunological complexity of human inflammatory bowel disease. The dose used (100 ug/kg IP) also represents a relatively high molar load compared to endogenous melanocortin peptide levels. Subsequent studies by the same group used nanoparticle-encapsulated KPV to achieve similar efficacy at lower doses.

Study 4: Pickart and Margolina (2018) - Systemic Overview and Nrf2 Evidence

The 2018 review by Pickart and Margolina in the journal Biomolecules synthesized over 40 years of GHK-Cu research and presented new mechanistic analysis linking GHK-Cu to Nrf2 pathway activation. ^[7] The authors analyzed published gene-chip data and identified a statistically significant overlap between GHK-Cu-responsive genes and the canonical Nrf2-ARE target gene set, including NQO1, HMOX1, GCLC, and TXNRD1.

The review also highlighted the paradox of GHK-Cu's apparently bidirectional effects on MMP activity: stimulating MMP production in wound models where matrix remodeling is beneficial, while suppressing MMP overactivation in fibrosis models where excess matrix degradation is harmful. The authors attributed this context-dependence to the cellular redox environment: in oxidative-stress conditions (fibrosis, aging), GHK-Cu's Nrf2 activation dominates and reduces MMP-driven damage; in low-inflammatory wound conditions, the peptide's growth-factor-like signaling dominates and promotes productive remodeling. This conceptual framework helps explain why in-vitro results from different research groups appear superficially contradictory.

Study 5: Rajabi et al. (2019) - GHK-Cu in Neurodegeneration Models

A 2019 study published in Brain Research investigated GHK-Cu in a rodent model of traumatic brain injury (TBI), administering the peptide at 5 mg/kg IP for seven days post-injury in male Sprague-Dawley rats (n = 10 per group). ^[10] Compared to vehicle-treated TBI animals, GHK-Cu-treated animals showed significantly reduced lesion volume on MRI (p < 0.01), improved beam-walking motor scores, and elevated BDNF and NGF expression in perilesional cortex at 7 days.

The mechanism appeared to involve both direct neurotrophic gene activation and suppression of neuroinflammation as measured by reduced microglial CD68 immunoreactivity and lower cortical IL-6 concentration. The dose of 5 mg/kg IP in rodents extrapolates to an animal-equivalent dose, not a human clinical recommendation. This study is notable because it extends the research scope of GHK-Cu beyond wound healing and skin biology into central nervous system regenerative contexts, a direction that remains active but incompletely characterized in the literature.

Study 6: Sanchez-Garrido et al. (2017) - Alpha-MSH Fragments and Metabolic Inflammation

While not a KPV-specific study, Sanchez-Garrido and colleagues published important work in 2017 in Nature Communications characterizing the anti-inflammatory and metabolic effects of alpha-MSH fragment analogs, including the C-terminal region containing the KPV sequence. ^[11] Using diet-induced obese mice, they demonstrated that MC3R agonism (relevant to KPV's partial receptor activity) reduced hypothalamic and peripheral inflammatory signaling, normalizing adipokine profiles and improving insulin sensitivity. The study provides a mechanistic rationale for KPV's observed effects in metabolic inflammation models and contextualizes the receptor versus non-receptor debate: MC3R-mediated effects and direct NF-kB inhibition may act additively in tissues that express both the receptor and the NF-kB pathway.

Pharmacokinetics

GHK-Cu's pharmacokinetic behavior is strongly influenced by its copper-binding properties. The Cu²⁺ center increases plasma protein binding (primarily to albumin and ceruloplasmin) substantially compared to the apo-tripeptide, which extends effective tissue retention relative to what the short half-life of the peptide backbone alone would predict. ^[2] The copper can redistribute to endogenous copper carrier proteins and copper-dependent enzymes at the target tissue, which means the biological signal may persist beyond the measurable half-life of the intact peptide.

For KPV, the PepT1-mediated intestinal transport mechanism means that oral bioavailability to the colonic epithelium may actually be higher than systemic plasma bioavailability suggests, because the peptide is actively sequestered by colonocytes before reaching portal circulation. ^[6] This creates an unusual pharmacokinetic profile where local tissue exposure (gut epithelium) can exceed systemic plasma concentrations, which is favorable for gut-targeted research applications but complicates systemic bioavailability estimates.

Both peptides are small enough to be filtered by the glomerulus and are expected to undergo renal elimination as the primary clearance route, supplemented by peptidase activity in plasma and tissues. The proline residue in KPV provides partial resistance to proline-specific peptidases (prolinases), extending its plasma half-life modestly compared to proline-free analogs of similar molecular weight.

Purity and Verification

Certificate of Analysis: GHK-Cu

The most important analytical verification for GHK-Cu is confirmation that the copper complex is intact. HPLC alone cannot distinguish between a properly chelated GHK-Cu batch and a batch where the copper has partially dissociated, leaving a mixture of GHK and inorganic copper salts. Inductively coupled plasma mass spectrometry (ICP-MS) or ICP-OES copper content quantification should accompany the HPLC data. Theoretical copper content in GHK-Cu is 18.65% (w/w) based on the molecular formula C₁₄H₂₄CuN₆O₄. A CoA that shows copper content deviating significantly from this value indicates batch quality issues.

ESI-MS or MALDI-MS should show a dominant ion at m/z approximately 342 ([GHK-Cu + H]⁺, singly charged) with no significant fragments corresponding to free GHK (m/z 341 as [GHK + H]⁺, difficult to distinguish without high-resolution MS). High-resolution mass spectrometry (HRMS) at 4 decimal places is the most reliable way to confirm the copper complex, and premium research vendors should be able to provide HRMS data on request.

The blue-green color of the lyophilized powder is a visual quality indicator. A pure white or colorless powder claiming to be GHK-Cu should be treated with suspicion; it may represent uncomplexed GHK or an incorrectly prepared batch. Note, however, that color alone is not a quantitative purity indicator.

Certificate of Analysis: KPV

KPV is analytically simpler than GHK-Cu because it does not involve a metal complex. The CoA should show RP-HPLC purity ≥99% with a single dominant peak at the expected retention time, ESI-MS confirmation of m/z 302 ([KPV + H]⁺), and ideally an amino acid analysis trace confirming the 1:1:1 Lys:Pro:Val ratio. Endotoxin testing is particularly relevant for KPV because many in-vitro anti-inflammatory experiments use LPS challenges as positive controls, and contaminating endotoxin in the KPV preparation would create false negative results or confounded dose-response curves.

Independent Verification Approach

Researchers who want independent verification beyond the vendor CoA have several practical options. Third-party peptide analytical services (several academic core facilities and commercial labs such as Alphalyse or Quality Systems Group) accept small submitted samples for HPLC-MS analysis. A standard RP-HPLC-ESI-MS run on a 0.5-1 mg sample will confirm identity and purity for approximately $150-300 per compound. For studies requiring regulatory-quality documentation (e.g., IACUC submissions), having an independent CoA is strongly advisable.

For copper content verification in GHK-Cu specifically, most academic chemistry departments with ICP facilities will accept small collaboration requests. Dissolving 1-2 mg in 2% nitric acid and running ICP-OES provides a quantitative copper value that directly confirms or refutes the stated complex composition.

See our supplier evaluation guide for a detailed rubric on reading CoAs and assessing vendor credibility, and our guide to CoA interpretation for a step-by-step walkthrough.

Dosage and Reconstitution

Reconstitution Principles

Both GHK-Cu and KPV dissolve readily in sterile water or phosphate-buffered saline (PBS, pH 7.4). Bacteriostatic water (0.9% benzyl alcohol) is commonly used for research vials to extend working solution stability; however, for cell-culture applications, sterile water for injection or endotoxin-free PBS is preferred to avoid benzyl alcohol toxicity to cultured cells at higher concentrations.

GHK-Cu reconstitution should be performed at room temperature with gentle swirling, not vortexing. Vigorous mechanical agitation can disrupt the copper complex and introduce oxidative byproducts. The solution should be a clear blue-green or teal color at concentrations of 1-10 mg/mL; a colorless solution suggests copper dissociation. Reconstituted GHK-Cu should be stored at 4°C and used within 7 days. Avoid repeated freeze-thaw cycles (maximum 2-3).

KPV reconstitutes easily and produces a clear, colorless solution. It is stable in solution at 4°C for approximately 14 days. Unlike GHK-Cu, KPV tolerates pH values across a wider range (4 to 9) without significant degradation. For oral dosing experiments in rodents, KPV has been dissolved in sterile saline or PBS with no carrier required.

For detailed step-by-step reconstitution guidance, see our comprehensive peptide reconstitution guide.

Worked Numerical Examples

Example 1: GHK-Cu stock solution for in-vitro fibroblast experiments

Target: 1 mM stock solution from 50 mg GHK-Cu. Calculation: MW = 340.84 g/mol. To prepare 1 mM (1 millimole per liter = 340.84 mg/L), dissolve 50 mg in volume V such that [50 mg / 340.84 g/mol] / V = 1 mM. Moles in 50 mg = 50/340.84 = 0.1467 mmol. For a 1 mM stock, V = 0.1467 mmol / 1 mM = 146.7 mL. In practice, researchers typically prepare a smaller concentrated stock. A 10 mM stock: V = 0.1467 mmol / 10 mM = 14.67 mL. This 10 mM stock is then diluted 10-fold to reach working concentrations of 1 mM, or 100-fold for 100 uM, or 10,000-fold for 1 uM.

Literature-reported fibroblast stimulation in wound healing models spans 1 nM to 10 uM, with most gene-expression experiments using 1 uM as the primary concentration.

Example 2: KPV for rodent IP colitis experiment

Reference dose from Dalmasso 2008: 100 ug/kg IP in C57BL/6 mice (average weight approximately 25 g). Per-animal dose = 100 ug/kg x 0.025 kg = 2.5 ug per mouse. For 15 mice: total KPV needed = 37.5 ug = 0.0375 mg. From a 10 mg vial, prepare a stock solution of 1 mg/mL in sterile saline: 10 mg in 10 mL. Working solution for IP injection: dilute 1:100 to get 10 ug/mL. Injection volume per mouse: 2.5 ug / 10 ug/mL = 0.25 mL per mouse (appropriate IP volume for 25g mouse). This 10 mg vial therefore contains sufficient material for approximately 4,000 mouse-doses at this research concentration.

Example 3: GHK-Cu topical preparation for wound-healing tissue culture model

Many published ex-vivo wound models apply GHK-Cu to skin explants at 10 uM in culture medium. MW = 340.84 g/mol. 10 uM = 10 x 10⁻⁶ mol/L = 3.408 mg/L = 3.408 ug/mL. For 10 mL of medium: mass needed = 34.08 ug = 0.034 mg. From 50 mg vial, prepare a 1 mg/mL stock in PBS (50 mg in 50 mL). Working solution: 34.08 uL of stock per 10 mL medium. The 50 mg vial at this concentration supports approximately 14,680 10-mL culture medium preparations.

For guidance on dosage calculations and dilution math, see our peptide dosage calculation guide.

Side Effects and Safety

GHK-Cu: Observed Safety Profile in Research Models

GHK-Cu has a generally favorable preclinical safety profile across the published literature, likely reflecting its origin as an endogenous human plasma peptide. Acute toxicity studies in rodents have not identified an LD50 within practical research dose ranges. At doses up to 50 mg/kg IP in rats, no overt toxicity signals have been reported in published protocols. ^[3] The copper content is a theoretical concern: excessive copper supplementation is associated with hepatotoxicity in both rodents and humans at pharmacological doses. However, the molar quantity of copper in research doses of GHK-Cu is small relative to toxic copper thresholds. A 5 mg/kg dose in a 25g mouse delivers approximately 7.5 ug of Cu²⁺, which is well below established rodent hepatotoxic copper doses.

In cell culture, concentrations of GHK-Cu exceeding 100 uM have been associated with pro-oxidant effects in some cell types, particularly those with high endogenous copper-enzyme activity. This is consistent with the known hormetic pharmacology of copper: low concentrations support enzymatic antioxidant activity, while high concentrations can catalyze Fenton-like oxidative reactions. Researchers should verify their concentration range does not enter the pro-oxidant zone for their cell type of interest.

Topical application of GHK-Cu in animal skin models has not produced contact sensitization, irritation, or histopathological dermal changes at concentrations up to 5% in standard vehicles. ^[9]

KPV: Observed Safety Profile in Research Models

KPV's preclinical safety data is largely restricted to the colitis model literature, which uses relatively acute short-course dosing protocols. In DSS colitis studies lasting 7 to 14 days, KPV at 100-300 ug/kg IP produced no body weight loss attributable to treatment, no gross organ toxicity at necropsy, and no histological evidence of off-target inflammation. ^[6] The partial melanocortin receptor activity raises a theoretical concern about effects on pigmentation, energy balance, and adrenal function at higher doses or with chronic administration, but no such effects have been reported in published short-duration studies.

Because KPV contains a lysine residue with a free epsilon-amino group, there is theoretical potential for non-enzymatic glycation in in-vitro systems with high glucose concentration. Researchers running KPV experiments in high-glucose diabetic cell models should be aware of this and use appropriate vehicle controls.

Open Safety Research Questions

Several safety-relevant questions remain unanswered in the peer-reviewed literature. First, the chronic-exposure safety profile of GHK-Cu at biologically active doses has not been systematically characterized in long-duration rodent studies. Second, the immunomodulatory effects of KPV at melanocortin receptors in the context of chronic inflammation or autoimmunity have not been explored in models beyond acute DSS colitis. Third, the interaction of exogenous GHK-Cu with endogenous copper homeostasis (ceruloplasmin, metallothionein, ATP7A/ATP7B copper transporters) is incompletely characterized, which is relevant for any model involving copper metabolism disorders.

How It Compares

Contextual Comparison: GHK-Cu vs BPC-157

Both GHK-Cu and BPC-157 are widely studied research peptides in the tissue-repair category, but they represent mechanistically distinct approaches. BPC-157 (body protective compound-157) is a 15-amino acid synthetic peptide derived from the body-protective protein sequence in human gastric juice, and its primary documented mechanisms involve focal adhesion kinase (FAK) activation, VEGFR2-mediated angiogenesis, and nitric oxide synthase upregulation. ^[12] GHK-Cu, by contrast, operates primarily through copper-dependent enzyme activation, Nrf2-ARE antioxidant signaling, and broad fibroblast transcriptional remodeling.

In wound healing models, BPC-157 tends to show faster early angiogenic effects while GHK-Cu shows more pronounced collagen quality remodeling in the maturation phase. They are not directly competitive for research application; investigators studying the full wound-healing cascade might find value in both, applied at different experimental timepoints. See our BPC-157 product review for a detailed analysis of that peptide's evidence base.

Contextual Comparison: KPV vs Alpha-MSH Analogs

KPV occupies an interesting niche relative to other melanocortin peptides. Full-length alpha-MSH (13 amino acids) has stronger MC1R and MC3R affinity than KPV, but the smaller tripeptide's ability to be transported via PepT1 and to act through receptor-independent NF-kB mechanisms gives it distinct research utility in gut-specific models. Researchers focused on systemic melanocortin effects would typically use MC3R or MC4R agonists with higher receptor selectivity. Researchers focused on gut-barrier biology find KPV uniquely well-suited because of its epithelial transport properties.

The synthetic melanocortin analog Melanotan II has broader pharmacological effects across multiple receptor subtypes and a more complex safety profile, making it less suitable for focused anti-inflammatory mechanistic work. KPV's limited receptor profile (partial MC1R/MC3R) and primary NF-kB mechanism make it more tractable for clean dissection of anti-inflammatory pathways.

Contextual Comparison: The Combination Concept

The pairing of GHK-Cu with KPV in a single vial is scientifically defensible on pathway grounds. GHK-Cu operates upstream via Nrf2 antioxidant gene activation and collagen synthesis, addressing oxidative stress and structural repair. KPV targets NF-kB downstream inflammatory cytokine production and gut-barrier integrity. In gut-injury models with an inflammatory component, these mechanisms are complementary rather than redundant. However, no published study has directly tested GHK-Cu plus KPV as a combination treatment. The combination rationale is inferential from individual mechanisms, which is a limitation researchers should acknowledge in experimental design.

Where to Buy

Apollo Peptide Sciences offers this combined vial through their research peptide catalog. For full pricing, purity documentation, and ordering information, see our GHK-Cu 50mg + KPV 10mg product page, which includes the most current CoA availability information and affiliate disclosure.

When evaluating research peptide suppliers more broadly, the key criteria are: HPLC purity documentation with traceable chromatograms (not just a stated percentage), mass spectrometry identity confirmation, ICP analysis for metal-containing peptides (GHK-Cu specifically), endotoxin testing for cell-culture grade products, and transparent return/retest policies for failed batches. Our research peptide supplier guide covers these criteria in detail with vendor-specific comparisons.

Apollo Peptide Sciences has provided CoA documentation including HPLC and ESI-MS data on publicly available product pages for this SKU. Researchers should request the copper content ICP data specifically when ordering GHK-Cu, as this is not always included by default in vendor CoAs. The $85.00 price point for 50 mg GHK-Cu plus 10 mg KPV is competitive: standalone 50 mg GHK-Cu typically retails between $70-100 from most vendors, and standalone 10 mg KPV typically costs $60-90, making the combined vial significantly more cost-efficient for investigators using both peptides.

Pharmacological Context and Adaptation Biology

Understanding GHK-Cu and KPV in their broader biological context requires situating them within the body's endogenous tissue-damage response system. Plasma GHK concentrations are not static: they rise following tissue injury, inflammatory challenge, and surgical stress, following a temporal pattern consistent with a mobilization signal for repair processes. ^[2] This has led several researchers to characterize GHK-Cu as an "injury-response peptide" rather than a constitutive growth signal, which may explain its generally favorable safety profile (endogenous peptides rarely exhibit toxicity within physiological concentration ranges) and its pleiotropic effects (injury repair requires simultaneous coordination of multiple cell types and processes).

Alpha-MSH and its fragments, including KPV, are released from pituitary and skin keratinocytes in response to UV stress, infection, and inflammatory stimuli. ^[4] This positions KPV as part of the skin and gut's peripheral neuroendocrine response to damage, paralleling GHK-Cu's role as a plasma-borne repair signal. The evolutionary conservation of these short peptide sequences across mammalian species suggests strong selective pressure to maintain their biological functions, which is consistent with the reproducibility of their effects across rodent models.

The concept of hormesis is relevant to both peptides. GHK-Cu, like many copper-binding compounds, has a biphasic dose-response curve: low nanomolar concentrations stimulate antioxidant gene expression and repair signaling, while high micromolar concentrations can become pro-oxidant. ^[7] Designing in-vitro experiments without considering this biphasic behavior can produce confusing results, particularly in studies using concentrations greater than 10 uM. Standard practice in the literature is to test at least three to four concentrations spanning two to three orders of magnitude to characterize the dose-response shape before committing to a single research concentration.

KPV similarly shows maximal NF-kB inhibition within a relatively narrow concentration window in cell culture. Below approximately 100 nM, effects are typically below the noise threshold of standard ELISA cytokine assays. Above approximately 10 uM, high concentrations may activate stress responses that confound anti-inflammatory readouts. The optimal window for most published KPV cell-culture studies is 1 nM to 1 uM, with the IC50 for NF-kB activation varying by cell type and stimulus (typically reported between 10 nM and 500 nM in macrophage models). ^[5]

Open Research Questions

Several significant gaps in the published literature warrant acknowledgment.

First, the synergistic or additive effects of GHK-Cu and KPV administered simultaneously have not been characterized in any published study. Preclinical proof-of-concept for the combination format awaits formal investigation. Researchers using this combined vial are operating in a literature-informed but untested combinatorial space, which can be scientifically valuable as original research but should be framed accordingly in protocols and publications.

Second, GHK-Cu's effects on copper metabolism homeostasis in chronic dosing models are poorly characterized. Most published in-vivo studies use acute or short-course dosing (7-14 days). The impact of continuous GHK-Cu administration on hepatic copper accumulation, ceruloplasmin dynamics, and metallothionein expression in long-duration experiments (months) has not been systematically reported. For any research program planning extended dosing periods, this represents an important gap that may require custom safety monitoring endpoints.

Third, KPV's mechanism in non-intestinal tissues is undercharacterized relative to its gut biology. Several published papers report anti-inflammatory effects of alpha-MSH fragments in skin, brain, and joint tissues, but KPV-specific mechanistic data outside the GI tract is sparse. Whether PepT1-independent uptake mechanisms operate in these tissues, and whether the relative contribution of NF-kB inhibition versus melanocortin receptor engagement differs by tissue, are open questions.

Fourth, the interaction of both peptides with the gut microbiome has not been investigated. KPV's documented effects on gut-barrier integrity would be expected to secondarily affect microbial community composition, and copper-dependent antimicrobial activity of GHK-Cu in the gut lumen is plausible but untested. Microbiome-dependent effects could confound or enhance observed outcomes in oral administration studies. ^[13]

Fifth, no head-to-head comparison of GHK-Cu versus KPV (or versus their combination) against standard-of-care anti-inflammatory agents in a validated animal disease model has been published. Such a comparison would substantially strengthen the translational rationale for either peptide in future clinical development.

Additional Research Perspectives

GHK-Cu in Aging Biology

The decline in plasma GHK concentrations with age (from approximately 200 nM in young adults to approximately 80 nM in older adults) has attracted interest from aging biology researchers. ^[3] Supplementation of GHK-Cu to aged rodent cells in culture has been shown to partially reverse age-associated decreases in collagen production and antioxidant gene expression, and to reduce expression of pro-inflammatory senescence-associated secretory phenotype (SASP) markers. This positions GHK-Cu as a potential research tool for studying the biology of cellular aging and senescence, though human clinical evidence for anti-aging effects remains absent.

Anisimov and colleagues, who have published extensively on peptide bioregulators and aging in rodent models, have contributed relevant background literature connecting small peptides (including copper-binding fragments) to longevity endpoints in rodents, though their work focuses primarily on thymic and pineal peptides rather than GHK-Cu directly. ^[14] The broader peptide-bioregulator framework they have established provides useful conceptual context for interpreting GHK-Cu's pleiotropic transcriptional effects.

KPV and Nanoparticle Drug Delivery

A developing application area for KPV involves its use as a payload in nanoparticle formulations designed for targeted gut delivery. Laroui and colleagues published work on KPV-loaded hydrogel nanoparticles that protected the peptide from gastric degradation and achieved sustained release in the colonic epithelium, enhancing efficacy approximately three-fold compared to free KPV oral administration in DSS colitis mice. ^[15] This nanoparticle approach is relevant for researchers interested in oral drug delivery applications, and it demonstrates that KPV's biological activity is robust enough to remain meaningful through encapsulation and release processes.

The nanoparticle platform also provides a model for studying KPV pharmacokinetics with improved resolution, since labeled nanoparticle tracking allows spatial and temporal distribution mapping that is difficult to achieve with free peptide. For investigators focused on pharmacokinetics and biodistribution research, KPV in conjunction with nanoparticle carrier systems represents an active and tractable research direction.

Collagen Quality and Scar Remodeling

One of the more clinically interesting areas of GHK-Cu research concerns its potential to shift wound repair from scar formation toward regenerative healing. The ratio of type I to type III collagen in healed tissue is a recognized marker of wound quality: high type I (tensile strength, organized fibrils) indicates mature remodeling, while high type III (loose, immature collagen) indicates persistent scar tissue. Multiple in-vitro and rodent wound studies have shown that GHK-Cu treatment increases the type I:III collagen ratio in healing tissue. ^[8] The molecular mechanism involves differential regulation of COL1A1 versus COL3A1 promoter activity via Sp1 binding sites, with GHK-Cu preferentially upregulating COL1A1. This is mechanistically distinct from TGF-beta1-driven fibrosis, which tends to elevate both collagen types, and may explain why GHK-Cu does not exacerbate fibrosis in the models where it has been tested.

FAQ